Drug Profile


Alternative Names: HPT-721; PDC-APB

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ElSohly Laboratories; University of Mississippi
  • Developer Hapten Sciences
  • Class Immunotherapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Contact dermatitis

Most Recent Events

  • 07 Mar 2016 Hapten Sciences plans a phase I trial for Contact dermatitis (In volunteers) in USA (NCT02700373)
  • 01 Mar 2016 Phase-I clinical trials in Contact dermatitis (In volunteers) in USA (IM) (NCT02700373)
  • 19 Nov 2015 Hapten Sciences files an IND application with the FDA in USA for Contact dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top